DT
HealthMore in Health→
Early Trial Signals Lower Relapse, Less Severe GVHD After Allogeneic Transplant
A Phase I result highlighted by Medical Xpress points to a transplant regimen that may reduce both relapse risk and severe graft-versus-host disease after donor stem cell transplantation.
Key Takeaways
- Medical Xpress highlighted a Phase I trial result for the VIC-1911 regimen.
- The supplied source text says patients had lower relapse risk and lower rates of graft-versus-host disease.
DE
DT Editorial Team··via medicalxpress.com